ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2301

Facing Fibromyalgia; How Patients Describe Their Symptoms Based on a Retrospective Evaluation of a Patient Survey and Vitality Assessment in Clinical Trials

Andrew Clair1, Lynne Pauer2 and Elizabeth Masters1, 1Pfizer Inc., New York, NY, 2Pfizer Inc, New London, CT

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: fibromyalgia

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Fibromyalgia (FM) is a common chronic widespread pain disorder with comorbid symptoms of fatigue, sleep disturbance, cognitive dysfunction and depression.  It is believed to be a central pain processing disorder.  Results of a recent patient survey conducted in the United States showed that those diagnosed with FM are misunderstood regarding condition severity, debilitating pain experienced and the impact it has on their lives.  These factors may lead to damaged relationships, lost productivity and a general inability to perform daily tasks.  In this assessment, we evaluated pain descriptors provided by FM survey respondents as well as baseline SF-36 vitality scores from 4 clinical trials to better understand the patient experience with FM pain and FM health status burden.

Methods: The Functioning with Fibro Survey was carried out in August 2013 and included 1,223 Americans ≥18 years old with fibromyalgia.   Participants had received an FM diagnosis from a healthcare provider and provided survey responses through an online data collection tool.  Separately, SF-36 vitality scale baseline data from 4 placebo-controlled Phase 3 FM clinical studies was assessed (range: 0-100; higher = better functioning). Subjects across the 4 clinical studies had FM diagnoses (1990 ACR criteria) with mean baseline pain scores ≥4 (0-10; higher = worse pain), and scores ≥40 mm on a Visual Analog Scale (range: 0-100; higher = worse pain).

Results: Survey results demonstrated that fibromyalgia pain is experienced differently across FM patients.  In response to the survey question, “If you had to describe to a friend how your fibromyalgia pain feels, which of the following situations comes closest to what you would say?”, the following was observed: radiating pain all over: 30%; getting run over by a truck: 28%; constant flu-like ache: 23%; stabbed by a knife: 10%; strenuous workout: 10%

Baseline mean SF-36 vitality scores ranged from 18.4 to 27.6 across the 4 clinical trials. For comparison, normative data for the US general population for women between ages 45–54 in 1998, was 60.6 (mean); standard deviation 21.3 (Hoffman et al. Int J Clin Pract. 2008:115-126). 

Conclusion: Fibromyalgia patients often experience debilitating pain which may impact multiple areas of their lives.  In a patient-rated survey of over 1,200 FM sufferers, pain was characterized in different ways but all were descriptive of debilitating pain.  SF-36 vitality scores at baseline from 4 FM studies confirmed significant vitality impairment. These scores reflected lower vitality than what has been reported for many other health conditions widely accepted as impairing, including COPD, congestive heart failure, diabetes, clinical depression, RA, OA, SLE, primary Sjogren’s Syndrome and Myofascial Pain Syndrome (Hoffman et al). Decreases in vitality scores are significantly associated with increased odds of negative outcomes, including inability to work due to health, job loss, increased hospitalization, and short and long-term mortality (Bjorner et al. Curr Med Res Opinion. 2007:731-739). These data underscore the important health burden in people with FM.


Disclosure: A. Clair, Pfizer Inc, 1,Pfizer Inc, 3; L. Pauer, Pfizer Inc, 3; E. Masters, Pfizer Inc, 3.

To cite this abstract in AMA style:

Clair A, Pauer L, Masters E. Facing Fibromyalgia; How Patients Describe Their Symptoms Based on a Retrospective Evaluation of a Patient Survey and Vitality Assessment in Clinical Trials [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/facing-fibromyalgia-how-patients-describe-their-symptoms-based-on-a-retrospective-evaluation-of-a-patient-survey-and-vitality-assessment-in-clinical-trials/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/facing-fibromyalgia-how-patients-describe-their-symptoms-based-on-a-retrospective-evaluation-of-a-patient-survey-and-vitality-assessment-in-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology